Real-world use of adjuvant nivolumab among patients with esophageal and gastroesophageal junction cancer at a large integrated health system

Authors

Andrea Gochi (ORCID: https://orcid.org/0000-0002-2917-451X)
Jeffrey B. Velotta (ORCID: https://orcid.org/0000-0002-1405-8487)
Gary J. Okano
Lisa Rosenblatt
Sydney Jeffs (ORCID: https://orcid.org/0000-0002-1761-8566)
Jingrong Yang (ORCID: https://orcid.org/0000-0003-1061-560X)
Reginald Villacorta
Yun‐Yi Hung
Tony Wang

Institutions

Kaiser Permanente (US)
Bristol-Myers Squibb (Germany) (DE)
Duke University (US)
California State University, East Bay (US)
Bristol-Myers Squibb (United States) (US)
University of California San Francisco Medical Center (US)
Colorado Permanente Medical Group (US)
East Bay Educational Collaborative (US)

Publication Details

Journal: JTCVS Open
Published: 2025-10-15
DOI: https://doi.org/10.1016/j.xjon.2025.10.003
Primary Topic: Esophageal Cancer Research and Treatment
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Real-world use of adjuvant nivolumab among patients with esophageal and gastroesophageal junction cancer at a large integrated health system

Andrea Gochi, Jeffrey B. Velotta, Gary J. Okano, Lisa Rosenblatt et al.

Oct 15, 2025

JTCVS Open

Esophageal Cancer Research and Treatment

article

Real-world use of adjuvant nivolumab among patients with esophageal and gastroesophageal junction cancer at a large integrated health system

Andrea Gochi, Jeffrey B. Velotta, Gary J. Okano, Lisa Rosenblatt, Sydney Jeffs, Jingrong Yang, Reginald Villacorta, Yun‐Yi Hung, Tony Wang

October 15, 2025article en

Abstract

No abstract available for this paper.

JTCVS OpenVol. 28

Kaiser Permanente (US), Bristol-Myers Squibb (Germany) (DE), Duke University (US), California State University, East Bay (US), Bristol-Myers Squibb (United States) (US), University of California San Francisco Medical Center (US), Colorado Permanente Medical Group (US), East Bay Educational Collaborative (US)

Openalex Percentile: Top 54%

Esophageal Cancer Research and Treatment

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Real-world use of adjuvant nivolumab among patients with esophageal and gastroesophageal junction cancer at a large integrated health system — Andrea Gochi, Jeffrey B. Velotta, et al. · JTCVS Open (2025) | TGRS Research Map | TGRS